Evolution of the Average Target: Treace Medical Concepts, Inc.

Evolution of the Average Target - Treace Medical Concepts, Inc.

Evolution of the Target Price: Treace Medical Concepts, Inc.

Evolution of the Target Price - Treace Medical Concepts, Inc.

Changes in Analyst Recommendations: Treace Medical Concepts, Inc.

5af0675e9a.KYLHbt0yQzD6OnGHzOjgyeyIotXuGS9yPd9CvKezFmM.G-WEMap0JQCiTDXjhauIv5bhl-WEKn1CCety9fPfLgpOt4wMl2J0A6p8NA~2046b8e124780503e63c583cd1162c3f
11-09 Treace Medical Concepts Shares Rise After Stifel Upgrade MT
11-09 Stifel Upgrades Treace Medical Concepts to Buy From Hold, Price Target is $6.50 MT
08-10 Truist Securities Adjusts PT on Treace Medical Concepts to $5 From $4, Keeps Hold Rating MT
07-16 Truist Securities Adjusts Price Target on Treace Medical Concepts to $4 From $2, Maintains Hold Rating MT
03-02 Truist Securities Adjusts Treace Medical Concepts PT to $2 From $3, Maintains Hold Rating MT
12-18 Truist Securities Trims Price Target on Treace Medical Concepts to $3 From $4, Maintains Hold Rating MT
11-10 Truist Cuts Price Target on Treace Medical Concepts to $4 From $7, Keeps Hold Rating MT
11-07 UBS Adjusts Price Target on Treace Medical Concepts to $5.85 From $6.50, Maintains Neutral Rating MT
11-07 JPMorgan Downgrades Treace Medical Concepts to Underweight From Neutral, Adjusts PT to $5 From $8 MT
11-07 BTIG Research Downgrades Treace Medical Concepts to Neutral From Buy MT
25-08-08 UBS Adjusts Treace Medical Concepts Price Target to $6.50 From $8.60, Maintains Neutral Rating MT
25-08-07 Treace Medical Q2 revenue edges above estimates RE
25-05-13 Morgan Stanley Cuts Price Target on Treace Medical Concepts to $8 From $10, Maintains Equalweight Rating MT
25-05-09 UBS Adjusts Price Target on Treace Medical Concepts to $8.60 From $10, Maintains Neutral Rating MT
25-04-11 Truist Cuts Price Target on Treace Medical Concepts to $8 From $9.50, Keeps Hold Rating MT
25-03-13 Truist Adjusts Price Target on Treace Medical Concepts to $9.50 From $10, Maintains Hold Rating MT
25-03-03 UBS Adjusts Treace Medical Concepts Price Target to $10 From $7.90, Maintains Neutral Rating MT
25-02-28 Truist Securities Adjusts Price Target on Treace Medical Concepts to $10 From $8.40, Keeps Hold Rating MT
25-02-04 BTIG Upgrades Treace Medical Concepts to Buy From Neutral, Price Target is $16 MT
24-12-31 Treace Medical Concepts Shares Rise After Lake Street Begins Coverage With Buy Rating MT
24-12-31 Lake Street Initiates Treace Medical Concepts at Buy With $14.50 Price Target MT
24-12-18 Truist Securities Adjusts Price Target on Treace Medical Concepts to $8.40 From $7, Keeps Hold Rating MT
24-10-14 Truist Lowers Price Target on Treace Medical Concepts to $6 From $7.50, Keeps Hold Rating MT
24-08-07 UBS Adjusts Treace Medical Concepts Price Target to $7 From $6.50, Maintains Neutral Rating MT
24-08-07 Truist Securities Adjusts Price Target on Treace Medical Concepts to $7.50 From $9, Maintains Hold Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+43.08%
+16.12%
+7.03%
+10.16%
+24.04%
+14.5%
+6.28%
+6.06%
+33.54%
+18.7%
Average +17.95%
Weighted average by Cap. +14.30%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
4.310USD
Average target price
6.167USD
Spread / Average Target
+43.08%
High Price Target
7.000USD
Spread / Highest target
+62.41%
Low Price Target
5.000USD
Spread / Lowest Target
+16.01%

Analyst Consensus Detail

Analyst consensus - Treace Medical Concepts, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Treace Medical Concepts, Inc.
Trader
Investor
-
Global
-
Quality
ESG MSCI
A
MarketScreener Ratings - Treace Medical Concepts, Inc.
  1. Stock Market
  2. Stocks
  3. TMCI Stock
  4. Consensus Treace Medical Concepts, Inc.